News
UNCY
5.43
+8.60%
0.43
Unicycive Therapeutics GAAP EPS of -$0.06 beats by $0.27
Seeking Alpha · 5h ago
*Unicycive Therapeutics: Unaudited Cash, Cash Equivalents, and Marketable Securities Totaled $61.4M at June 30, With Expected Runway Into 2027 >UNCY
Dow Jones · 6h ago
Press Release: Unicycive Therapeutics Announces -2-
Dow Jones · 6h ago
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate
Benzinga · 6h ago
Weekly Report: what happened at UNCY last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at UNCY last week (0727-0731)?
Weekly Report · 08/03 09:34
Weekly Report: what happened at UNCY last week (0720-0724)?
Weekly Report · 07/27 09:36
Unicycive Therapeutics: Two CRLs, One Fixable Problem
Seeking Alpha · 07/25 14:01
Weekly Report: what happened at UNCY last week (0713-0717)?
Weekly Report · 07/20 09:35
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Benzinga · 07/16 17:29
Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group
TipRanks · 07/14 08:25
Weekly Report: what happened at UNCY last week (0706-0710)?
Weekly Report · 07/13 09:35
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
Barchart · 07/08 19:00
Weekly Report: what happened at UNCY last week (0629-0703)?
Weekly Report · 07/06 09:37
Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position
TipRanks · 07/02 14:58
Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal
NASDAQ · 07/02 14:09
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Barchart · 07/01 18:00
Unicycive Therapeutics Price Target Cut to $13.00/Share From $18.00 by Benchmark
Dow Jones · 07/01 15:43
Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark
Dow Jones · 07/01 15:43
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13
Benzinga · 07/01 15:33
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.